These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22306908)

  • 1. Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Dobrzanski MJ; Lockwood-Cooke PR; Robinson W
    J Immunother; 2012; 35(2):196-204. PubMed ID: 22306908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
    Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
    Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
    Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and safety of adoptive immunotherapy with ex vivo-generated autologous, cytotoxic T lymphocytes in patients with solid tumor.
    Montagna D; Turin I; Schiavo R; Montini E; Zaffaroni N; Villa R; Secondino S; Schiavetto I; Caliogna L; Locatelli F; Libri V; Pession A; Tonelli R; Maccario R; Siena S; Pedrazzoli P
    Cytotherapy; 2012 Jan; 14(1):80-90. PubMed ID: 21942841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Number of treatment cycles influences development of cytotoxic T cells in metastatic breast cancer patients - a phase I/II study.
    Wright SE; Rewers-Felkins KA; Quinlin IS; Phillips CA; Townsend M; Philip R; Zorsky P; Klug P; Dai L; Hussain M; Thomas AA; Sundaramurthy C
    Immunol Invest; 2010; 39(6):570-86. PubMed ID: 20653425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human ovarian cancer stem-like cells can be efficiently killed by γδ T lymphocytes.
    Lai D; Wang F; Chen Y; Wang C; Liu S; Lu B; Ge X; Guo L
    Cancer Immunol Immunother; 2012 Jul; 61(7):979-89. PubMed ID: 22120758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival-a substudy of the MIMOSA trial.
    Buzzonetti A; Fossati M; Catzola V; Scambia G; Fattorossi A; Battaglia A
    Cancer Immunol Immunother; 2014 Oct; 63(10):1037-45. PubMed ID: 24952307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia.
    Turin I; Pedrazzoli P; Tullio C; Montini E; La Grotteria MC; Schiavo R; Perotti C; Locatelli F; Carretto E; Maccario R; Siena S; Montagna D
    Cytotherapy; 2007; 9(5):499-507. PubMed ID: 17786611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of ovarian tumor-specific CD8+ cytotoxic T lymphocytes by acid-eluted peptide-pulsed autologous dendritic cells.
    Santin AD; Bellone S; Ravaggi A; Pecorelli S; Cannon MJ; Parham GP
    Obstet Gynecol; 2000 Sep; 96(3):422-30. PubMed ID: 10960637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy for advanced cancer patients using in vitro activated cytotoxic T lymphocytes.
    Soda H; Koda K; Yasutomi J; Oda K; Takiguchi N; Saito N; Nakajima N
    J Surg Oncol; 1999 Dec; 72(4):211-7. PubMed ID: 10589036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
    Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer.
    Santin AD; Bellone S; Palmieri M; Bossini B; Cane' S; Bignotti E; Roman JJ; Cannon MJ; Pecorelli S
    Int J Gynecol Cancer; 2004; 14(1):64-75. PubMed ID: 14764031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic effects of T cells induced by fusion protein 6B11-pulsed dendritic cells on ovarian carcinoma cells.
    Yang W; Feng J; Chang X; Fu T; Ye X; Zhang H; Li X; Wen H; Feng L; Tong C; Cui H
    Gynecol Oncol; 2007 Apr; 105(1):238-43. PubMed ID: 17383546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Anti-tumor effect of cytotoxic T lymphocytes induced by soluble antigen of ovarian carcinoma and anti-CD3 monoclonal antibody on ovarian carcinoma].
    Zhang Q; Wan Y; Zhai H
    Zhonghua Fu Chan Ke Za Zhi; 1998 Jun; 33(6):355-7. PubMed ID: 10806675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody.
    Lamers CH; Bolhuis RL; Warnaar SO; Stoter G; Gratama JW
    Int J Cancer; 1997 Oct; 73(2):211-9. PubMed ID: 9335445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
    Li T; Wang J
    BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen-specific active immunotherapy for ovarian cancer.
    Leffers N; Daemen T; Helfrich W; Boezen HM; Cohlen BJ; Melief CJ; Nijman HW
    Cochrane Database Syst Rev; 2014 Sep; (9):CD007287. PubMed ID: 25229990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
    Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
    Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.